{"id":21623,"date":"2023-03-09T15:23:47","date_gmt":"2023-03-09T09:53:47","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=21623"},"modified":"2024-09-18T15:23:26","modified_gmt":"2024-09-18T09:53:26","slug":"medtech-news-for-artica-nevro-respiree-abbott","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott","title":{"rendered":"Artica Systems\u2019s Electric Whole-Body Cryotherapy Machines; Nevro\u2019s Revolutionary HFX iQ&#x2122; Spinal Cord Stimulation System; COBRA Study of Stratus\u00ae Medical for Nimbus\u00ae Radiofrequency Ablation Device; Restore Medical\u2019s CONTRABAND&#x2122; System; US FDA 510(k) Clearance for RS001 Cardio-respiratory Wearable; FDA Approval to Abbott\u2019s Traumatic Brain Injury (TBI) Blood Test"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a00aba6a626f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a00aba6a626f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\/#New_Commercial_Residential_Electric_Whole-Body_Cryotherapy_Machines_Released_by_Artica_Systems\" >New Commercial &amp; Residential Electric Whole-Body Cryotherapy Machines Released by Artica Systems&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\/#First_Patient_Enrolled_in_COBRA_Study_of_Stratus%C2%AE_Medical_for_Nimbus%C2%AE_Radiofrequency_Ablation_Device\" >First Patient Enrolled in COBRA Study of Stratus\u00ae Medical for Nimbus\u00ae Radiofrequency Ablation Device<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\/#Abbott_Received_FDA_Approval_for_the_First_Commercially_Available_Laboratory_Traumatic_Brain_Injury_TBI_Blood_Test\" >Abbott Received FDA Approval for the First Commercially Available Laboratory Traumatic Brain Injury (TBI) Blood Test&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\/#Restore_Medical_Announced_Successful_First-In-Human_Preliminary_Results_of_Its_CONTRABAND%E2%84%A2_System_for_Symptomatic_Systolic_Heart_Failure_Patients\" >Restore Medical Announced Successful First-In-Human Preliminary Results of Its CONTRABAND&#x2122; System for Symptomatic Systolic Heart Failure Patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\/#Nevro_Announced_US_Full_Market_Launch_of_Revolutionary_HFX_iQ%E2%84%A2_Spinal_Cord_Stimulation_System\" >Nevro Announced US Full Market Launch of Revolutionary HFX iQ&#x2122; Spinal Cord Stimulation System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\/#Respiree_Earned_US_FDA_510k_Clearance_for_RS001_Cardio-respiratory_Wearable\" >Respiree Earned US FDA 510(k) Clearance for RS001 Cardio-respiratory Wearable<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-new-commercial-residential-electric-whole-body-cryotherapy-machines-released-by-artica-systems\"><span class=\"ez-toc-section\" id=\"New_Commercial_Residential_Electric_Whole-Body_Cryotherapy_Machines_Released_by_Artica_Systems\"><\/span><strong>New Commercial &amp; Residential Electric Whole-Body Cryotherapy Machines Released by Artica Systems&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> March 2, 2023, <\/strong>Artica Systems, an American company with over 20 years of experience in the wellness industry announced the release of a new and innovative 100% electric, whole-body cryotherapy fleet meant for both commercial and residential use.<\/p>\n\n\n\n<p>The latest cryotherapy fleet provides the most adaptive and comfortable cryotherapy experience and possesses the following state-of-the-art features:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>-110F true air temperature (-165F with BreezeLink&#x2122;)<\/li>\n\n\n\n<li>BreezeLink&#x2122; technology, which has a patent pending, enables customers to alter wind speed and refrigerant flow rates from inside the cabin. A change in user-controlled therapy&#8217;s paradigm.&nbsp;<\/li>\n\n\n\n<li>Leading efficiency with estimated running costs of less than USD 8 per day.<\/li>\n\n\n\n<li>The smallest available engine. Averages up to 80% smaller than their European equivalents and 60% smaller than other US manufacturers.<\/li>\n\n\n\n<li>The quietest engine on the market (64dBA at 1m).<\/li>\n\n\n\n<li>A custom IoT-based networking app that puts diagnostics and control at your fingertips &#8211; right on your mobile phone or PC.<\/li>\n\n\n\n<li>CryoBoost&#x2122; for added capacity during peak demand in commercial units.<\/li>\n\n\n\n<li>Rapid-Defrost&#x2122; for maximum efficiency during extended use periods.<\/li>\n<\/ul>\n\n\n\n<p>Artica Systems gives individuals benefits for their body, brain, immune system, and metabolism by utilizing the power of cold exposure. It helps to fight inflammation and promote healthy immune cells, including cytotoxic T lymphocytes, which play a key role in protecting the body from cancer.&nbsp; The cryotherapy system is tailored and designed to work in a range of conditions for a broad spectrum of users.&nbsp;<\/p>\n\n\n\n<p>Evan Kuklinski, Founder &amp; Chief Engineer of Artica Systems said, <em>&#8220;We figured the best way to develop a breakthrough technology was to work together with our clients. People who religiously use cryotherapy every day.&#8221; <\/em>He added<em>, &#8220;We addressed our prototypes systematically and learned what made for good cryotherapy, together. It was a clever bit of collaborative innovation.&#8221;&nbsp;<\/em><\/p>\n\n\n\n<p>As per <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cryotherapy-market\"><strong>Cryotherapy Market<\/strong><\/a><strong>\u201d<\/strong> report, the global cryotherapy market was valued at <strong>USD 258.17 million<\/strong> in 2021, growing at a CAGR of <strong>8.01%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 408.44 million<\/strong> by 2027. The cryotherapy market is slated to witness prosperity owing to factors such as the increasing prevalence of chronic diseases such as cancer, neurological diseases, bone diseases, and others, increasing demand for healthy skin, rise in sports and other injuries, and the growing focus on improving the safety and usability of cryotherapy for end-users are further expected to result in the appreciable revenue growth in the cryotherapy market during the forecast period (2022-2027).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-patient-enrolled-in-cobra-study-of-stratus-medical-for-nimbus-radiofrequency-ablation-device\"><span class=\"ez-toc-section\" id=\"First_Patient_Enrolled_in_COBRA_Study_of_Stratus%C2%AE_Medical_for_Nimbus%C2%AE_Radiofrequency_Ablation_Device\"><\/span><strong>First Patient Enrolled in COBRA Study of Stratus\u00ae Medical for Nimbus\u00ae Radiofrequency Ablation Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>March 2, 2023<\/strong>, Stratus\u00ae Medical, a company focused on advancing radiofrequency (RF) ablation treatment for pain along with the University of Utah, Department of Physical Medicine and Rehabilitation announced the enrolment of the first patient in COBRA study, an IRB-approved, double-blinded, randomized trial, which aims to compare the bipolar treatment with Nimbus\u00ae RF Multitined Expandable Electrode to conventional radiofrequency ablation for the treatment of sacroiliac joint (SIJ) pain.<\/p>\n\n\n\n<p>The study supported by an investigator-initiated research grant from Stratus Medical expects to enrol up to 116 patients at the University of Utah and is going to be conducted at three-month, six-month, 12 months, 18-month, and 24-month endpoints. The major objective of the study is to quantify the effectiveness and duration of relief for the popular bipolar application in the sacroiliac joint.&nbsp;<\/p>\n\n\n\n<p><em>&#8220;This study will be one of the largest and best-designed SIJ RFA trials performed to date. We expect the results will significantly impact practice patterns regarding electrode choice for many physicians who treat SIJ pain and will further bolster the existing evidence for SIJ radiofrequency ablation. We thank Stratus Medical for their partnership in funding this important research,\u201d<\/em> commented Principle investigator, Dr. Aaron Conger, Assistant Professor and Interventional Spine and Musculoskeletal Medicine Physician at the University of Utah in the Department of Physical Medicine and Rehabilitation (PM&amp;R).&nbsp;<\/p>\n\n\n\n<p>Bret Boudousquie, Stratus Medical CEO, said, <em>&#8220;We are delighted to support this important investigator-initiated research comparing our highly differentiated and patented Nimbus RF technology to conventional RF needles for the treatment of sacroiliac joint pain.&nbsp; Nimbus is rapidly becoming the preferred large volume lesion nerve ablation technology to treat pain due to reproducible and sustained pain relief, faster procedure times, and lower procedure costs.&nbsp; We expect this research will further validate the significant clinical advantages of Nimbus compared to conventional RF needles.&#8221;<\/em><\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/ablation-devices-market\"><strong>Ablation Devices<\/strong><strong> <\/strong><strong>Market<\/strong><\/a><strong>\u201d<\/strong> report, the global ablation devices market is estimated to grow at a CAGR of <strong>11.65%<\/strong> during the forecast period from 2022 to 2027. Factors such as the increasing incidence of cancers such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/liver-cancer-market\"><strong>liver cancer<\/strong><\/a>, the rising prevalence of chronic pains such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/musculoskeletal-pain-market\"><strong>musculoskeletal pains<\/strong><\/a>, the rising prevalence of cardiac arrhythmias such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/atrial-fibrillation-market\"><strong>atrial fibrillation<\/strong><\/a>, and the rising regulatory approvals for technologically advanced ablation devices. Therefore, the market for ablation devices is estimated to grow at a significant CAGR during the forecast period from 2022 to 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbott-received-fda-approval-for-the-first-commercially-available-laboratory-traumatic-brain-injury-tbi-blood-test\"><span class=\"ez-toc-section\" id=\"Abbott_Received_FDA_Approval_for_the_First_Commercially_Available_Laboratory_Traumatic_Brain_Injury_TBI_Blood_Test\"><\/span><strong>Abbott Received FDA Approval for the First Commercially Available Laboratory Traumatic Brain Injury (TBI) Blood Test&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> March 7, 2023<\/strong>, Abbott, received the Food and Drug Administration (FDA) clearance for its Alinity i TBI lab test, making it the first commercially available <a href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-epidemiology-forecast\"><strong>laboratory test for traumatic brain injury (TBI)<\/strong><\/a>.&nbsp;<\/p>\n\n\n\n<p>The Abbott&#8217;s Alinity i TBI lab test which is designed to run on Abbott&#8217;s Alinity\u00ae i laboratory instrument enables clinicians to quickly assess individuals who are aged 18 years or older and are presenting with suspected mild traumatic brain injury, also known as concussions.&nbsp;<\/p>\n\n\n\n<p>It provides test results with 96.7% sensitivity and 99.4% negative predictive value by measuring the two complementary biomarkers in blood plasma and serum &#8211; Ubiquitin C-terminal Hydrolase L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP), that, in elevated concentrations, are tightly correlated to brain injury.&nbsp;<\/p>\n\n\n\n<p>The Alinity I test is suitable to use when a patient arrives at the hospital with a suspected mTBI within 12 hours of the injury.&nbsp; The test is conducted using the Alinity I equipment after a blood sample is taken from the arm and delivered to the lab for preparation. Findings are shared with the treating healthcare physician for assessment in as little as 18 minutes after being available.<\/p>\n\n\n\n<p>Along with assisting healthcare providers to decide upon appropriate next steps and develop a plan to care for patients, the TBI blood test also eliminates the need for a CT scan and can eliminate wait time at the hospital for patients with negative test results.&nbsp;<\/p>\n\n\n\n<p>The test already received European Union clearance and has been available in markets outside the US since 2021.<\/p>\n\n\n\n<p><em>&#8220;People sometimes minimize a hit to the head, thinking it&#8217;s no big deal. Others wonder if a visit to the doctor or emergency room for a possible concussion will provide them with meaningful answers or care,&#8221; <\/em>commented Beth McQuiston, M.D., medical director of Abbott&#8217;s diagnostics business.&nbsp; Beth added, <em>&#8220;Now that this test will be widely available in labs across the country, medical centers will be able to offer an objective blood test than can aid in concussion assessment. That&#8217;s great news for both doctors and people who are trying to find out if they have suffered a traumatic brain injury.&#8221;<\/em><\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-assessment-management-devices-market\"><strong>Traumatic Brain Injury Assessment Devices<\/strong> <strong>Market<\/strong><\/a>\u201d report, the global traumatic brain injury assessment devices market was valued at <strong>USD 2.8 billion<\/strong> in 2021, growing at a CAGR of <strong>8.57%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 4.57 billion<\/strong> by 2027. The Traumatic Brain Injury (TBI) assessment devices market is witnessing positive growth owing to various factors such as the increasing road traffic crashes cases, <a href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-epidemiology-forecast\"><strong>increasing prevalence of Traumatic Brain Injury<\/strong><\/a>, rising geriatric population, and increasing regulatory approvals &amp; launches of Traumatic Brain Injury (TBI) assessment devices. Therefore, the market for TBI assessment devices is estimated to grow at a significant CAGR during the forecast period from 2022 to 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-restore-medical-announced-successful-first-in-human-preliminary-results-of-its-contraband-system-for-symptomatic-systolic-heart-failure-patients\"><span class=\"ez-toc-section\" id=\"Restore_Medical_Announced_Successful_First-In-Human_Preliminary_Results_of_Its_CONTRABAND%E2%84%A2_System_for_Symptomatic_Systolic_Heart_Failure_Patients\"><\/span><strong>Restore Medical Announced Successful First-In-Human Preliminary Results of Its CONTRABAND&#x2122; System for Symptomatic Systolic Heart Failure Patients<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>March 7, 2023,<\/strong> -Restore Medical Ltd, a privately held medical device company, announced the successful completion of the first in a human clinical study with its CONTRABAND&#x2122; device, which is the world&#8217;s first and only Pulmonary Artery Banding (PAB) transcatheter implant device intended to treat and improve the quality of life for <a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-market\"><strong>heart failure patients<\/strong><\/a>.<\/p>\n\n\n\n<p>The CONTRABAND&#x2122; device places implants in the left and right pulmonary arteries to treat left ventricular (LV) failure. As a result, the failing LV&#8217;s ejection fraction is improved and the right ventricle&#8217;s (RV) favourable ventricular shape is restored.&nbsp;<\/p>\n\n\n\n<p>The CONTRABAND&#x2122; device improved the quality of life of the treated patients, according to the results of a feasibility, multi-center, prospective study that enrolled up to 15 patients in five hospitals in Europe who were already receiving maximally tolerated guideline-directed medical therapy (GDMT). The implantation procedure was safe for all participants, with excellent long-term right ventricular safety.&nbsp;<\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/transcatheter-aortic-valve-replacement-market\"><strong>Transcatheter Aortic Valve Replacement Devices Market<\/strong><\/a><strong>\u201d <\/strong>report, the global transcatheter aortic valve replacement (TAVR) devices market was valued at <strong>USD 3.23 billion<\/strong> in<strong> 2021<\/strong>, growing at a <strong>CAGR of 15.41%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 7.64 billion <\/strong>by<strong> 2027<\/strong>. The demand for transcatheter aortic valve replacement devices is primarily being boosted by the increasing prevalence of aortic stenosis disorder, rise in cardiovascular disorders, increasing demand for TAVR procedures, increasing prevalence of aortic regurgitation, and the technological advancements pertaining to the transcatheter aortic valve replacement arena which are expected to increase the product demand thereby contributing in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/transcatheter-aortic-valve-replacement-market\"><strong>growth of the transcatheter aortic valve replacement devices market<\/strong><\/a> during the forecast period from 2022-2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nevro-announced-us-full-market-launch-of-revolutionary-hfx-iq-spinal-cord-stimulation-system\"><span class=\"ez-toc-section\" id=\"Nevro_Announced_US_Full_Market_Launch_of_Revolutionary_HFX_iQ%E2%84%A2_Spinal_Cord_Stimulation_System\"><\/span><strong>Nevro Announced US Full Market Launch of Revolutionary HFX iQ&#x2122; Spinal Cord Stimulation System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> March 7, 2023, <\/strong>Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, initiated the full market launch of its HFX iQ spinal cord stimulation (SCS) system in the US.&nbsp;<\/p>\n\n\n\n<p>Based on the HFX Algorithm&#x2122;, which was developed using more than 20 million data points and 80,000 implanted patients, HFX iQ places patients on the program that is most likely to relieve their pain. To create a tailored program environment for each patient, HFX iQ blends clinical inputs such as pain alleviation and pain score with Quality of Life inputs such as pain medication and activity level changes.&nbsp; It offers the broadest variety of frequencies of any SCS system on the market, including low frequency and the business&#8217;s exclusive high-frequency 10 kHz Therapy&#x2122;. The improved Senza\u00ae high-frequency 10 kHz Treatment delivers distinctive AI-driven iQ modes designed for treating uncomfortable diabetic neuropathy (PDN) and chronic back and leg pain, including non-surgical back pain (NSBP). It has been validated in both clinical and real-world outcomes.&nbsp;<\/p>\n\n\n\n<p>The Senza HFX iQ system is comprised of the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, and HFX App. The patients can input assessments into their smartphones and can receive programming adjustments in real-time with a new Bluetooth\u00ae-enabled IPG that is upgradeable and connects directly to the HFX App.&nbsp;<\/p>\n\n\n\n<p>Dr. Usman Latif, MD, MBA, a Harvard-trained interventional pain specialist who practices at the University of Kansas Medical Center said, <em>&#8220;This is an exciting time in spinal cord stimulation &#8212; better waveforms, more conditions we can treat, and a massive treasure trove of patient data.&#8221; <\/em>Dr. Latif added<em>, \u201cThe way forward in this field is precision medicine powered by big data and artificial intelligence. Our limitations are human in nature. What if we could take all the programming experience and clinical outcomes of tens of thousands of patients across the country, including what programs worked and what didn&#8217;t, and bring the power of all that knowledge into the palm of our patient&#8217;s hand &#8212; with them 24\/7, monitoring them, and offering them the best program for their exact situation with a tap on the screen. HFX iQ is the future of medicine, where expanded data holds the promise of new capabilities and improved care.&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;We are continuing to lead the way with the first big data-backed, AI-powered SCS system that gets smarter over time, learning from patient responses to deliver personalized relief to patients,&#8221; <\/em>commented D. Keith Grossman, Chairman, CEO, and President of Nevro<em>. <\/em>Keith added,<em> &#8220;With over 10 years of innovation and now over 100,000 patients served, Nevro brings the next big advancement to SCS therapy with HFX iQ, a system that will apply the big data we have collected over the last decade to help patients find pain relief faster and maintain that relief over time. We believe that what we&#8217;re doing with HFX iQ is the future of SCS therapy, and keeps Nevro firmly at the forefront of innovation, as we continue to work with our clinicians to bring new technology, new data, and new indications to their patients.&#8221;<\/em><\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-stimulator-market\"><strong>Spinal Cord Stimulators (SCS) Market<\/strong><\/a><strong>\u201d <\/strong>report, the global spinal cord stimulators market was valued at <strong>USD 2.25 billion<\/strong> in 2021, growing at a CAGR of <strong>8.70%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 3.72 billion<\/strong> by 2027. The demand for Spinal Cord Stimulators (SCS) is primarily attributed to the growing number of <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-epidemiology-forecast\"><strong>patients with chronic pain<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuropathic-pain-epidemiology-forecast\"><strong>neuropathic pain<\/strong><\/a> in the shoulder, legs, and knee. The technologically advanced devices that are non-invasive to eliminate targeted pains and cause a reduction in patient discomfort with no side effects are likely responsible for a boost in the Global Spinal Cord Stimulators (SCS) Market growth. Moreover, favorable government regulations for commercialization and launching products in the market and the rising geriatric population are some of the factors responsible for propelling the growth of the Spinal Cord Stimulators (SCS) Market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-respiree-earned-us-fda-510-k-clearance-for-rs001-cardio-respiratory-wearable\"><span class=\"ez-toc-section\" id=\"Respiree_Earned_US_FDA_510k_Clearance_for_RS001_Cardio-respiratory_Wearable\"><\/span><strong>Respiree Earned US FDA 510(k) Clearance for RS001 Cardio-respiratory Wearable<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>March 8, 2023<\/strong>, Respiree, a digital therapeutics company providing personalized healthcare services for cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI, and workflow-integrated UIUX received the 510(k) clearance from the United States Food and Drug Administration for its RS001 cardio-respiratory wearable.<\/p>\n\n\n\n<p>The RS001, intended for patients suffering from cardio-pulmonary diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\"><strong>chronic obstructive pulmonary disease (COPD)<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-market\"><strong>congestive heart failure<\/strong><\/a>, is a chest wearable that measures respiration directly.&nbsp;<\/p>\n\n\n\n<p>Respiree intends to seek additional 510(k) clearances with the help of its initial approval for its expanded indications for use and software that will make use of the RS001&#8217;s proprietary respiratory digital biomarkers to forecast the progression of conditions in diseases like COPD and congestive heart failure. RS001 is already CE-marked and approved for use in Australia by the Therapeutics Goods Administration (TGA).&nbsp;<\/p>\n\n\n\n<p>Respiree&#8217;s CEO and Founder Dr. Gurpreet Singh said<em>, &#8220;COPD exacerbations drive both morbidity and mortality. It is important to be able to identify them early and prevent them with the right therapeutic. By using Respiree&#8217;s RS001, physicians can now have the opportunity to identify exacerbations not hours or minutes in advance, but days in advance. This can enable patients to quickly receive preventive care before exacerbation onset.\u201d<\/em><\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/wearable-medical-devices-market\"><strong>Wearable Medical Devices Market<\/strong><\/a><strong>\u201d<\/strong> report, the global wearable medical devices market is estimated to grow at a CAGR of <strong>13.67%<\/strong> during the forecast period from 2022 to 2027. The wearable medical devices market is witnessing positive growth primarily due to the rising prevalence of chronic diseases such as cardiovascular, diabetes, pain, and others. Further, the rising burden of the geriatric population prone to various chronic diseases across the globe, the increasing awareness about fitness &amp; physical activity, the increasing regulatory approval for wearable medical devices across the globe along with the presence of key players will in turn, surge the <a href=\"https:\/\/www.delveinsight.com\/blog\/wearable-technology-trends-2022\"><strong>demand for wearable medical devices<\/strong><\/a> during the forecast period. Therefore, the market for <a href=\"https:\/\/www.delveinsight.com\/blog\/medical-robots-market\"><strong>wearable medical devices<\/strong><\/a> is expected to grow during the forecast period from 2022 to 2027.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Commercial &amp; Residential Electric Whole-Body Cryotherapy Machines Released by Artica Systems&nbsp; On March 2, 2023, Artica Systems, an American company with over 20 years of experience in the wellness industry announced the release of a new and innovative 100% electric, whole-body cryotherapy fleet meant for both commercial and residential use. The latest cryotherapy fleet [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":21626,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":9,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2405,19675,19674,20456,2033,20095,2753,17020,17021,16779,16975,18799,420,20460,20461,18985,20457,17987],"industry":[17226],"therapeutic_areas":[17241,17245,17228],"class_list":["post-21623","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbott","tag-ablation-devices","tag-ablation-devices-market","tag-artica-systems","tag-cryotherapy","tag-cryotherapy-market","tag-medical-device","tag-medical-devices","tag-medical-devices-market","tag-medtech","tag-medtech-market","tag-medtech-news","tag-news","tag-restore-medical","tag-spinal-cord-stimulation","tag-spinal-cord-stimulation-system","tag-stratus-medical","tag-traumatic-brain-injury","industry-medical-devices","therapeutic_areas-musculoskeletal","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Artica, Nevro, Restore Medical, Respiree, Abbott<\/title>\n<meta name=\"description\" content=\"Artica&#039;s Cryotherapy Machines; Abbott\u2019s TBI Blood Test; Restore Medical\u2019s CONTRABAND System; Nevro\u2019s HFX iQ\u2122 SCS System; Respiree&#039;s RS001\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Artica, Nevro, Restore Medical, Respiree, Abbott\" \/>\n<meta property=\"og:description\" content=\"Artica&#039;s Cryotherapy Machines; Abbott\u2019s TBI Blood Test; Restore Medical\u2019s CONTRABAND System; Nevro\u2019s HFX iQ\u2122 SCS System; Respiree&#039;s RS001\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-09T09:53:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:53:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/09152207\/MedTech-News-for-Artica-Systems-Nevro-Stratus%C2%AE-Medical-Restore-Medical-Respiree-Abbott.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Artica, Nevro, Restore Medical, Respiree, Abbott","description":"Artica's Cryotherapy Machines; Abbott\u2019s TBI Blood Test; Restore Medical\u2019s CONTRABAND System; Nevro\u2019s HFX iQ\u2122 SCS System; Respiree's RS001","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Artica, Nevro, Restore Medical, Respiree, Abbott","og_description":"Artica's Cryotherapy Machines; Abbott\u2019s TBI Blood Test; Restore Medical\u2019s CONTRABAND System; Nevro\u2019s HFX iQ\u2122 SCS System; Respiree's RS001","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-03-09T09:53:47+00:00","article_modified_time":"2024-09-18T09:53:26+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/09152207\/MedTech-News-for-Artica-Systems-Nevro-Stratus%C2%AE-Medical-Restore-Medical-Respiree-Abbott.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott","name":"MedTech News | Artica, Nevro, Restore Medical, Respiree, Abbott","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/09152207\/MedTech-News-for-Artica-Systems-Nevro-Stratus%C2%AE-Medical-Restore-Medical-Respiree-Abbott.png","datePublished":"2023-03-09T09:53:47+00:00","dateModified":"2024-09-18T09:53:26+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Artica's Cryotherapy Machines; Abbott\u2019s TBI Blood Test; Restore Medical\u2019s CONTRABAND System; Nevro\u2019s HFX iQ\u2122 SCS System; Respiree's RS001","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-artica-nevro-respiree-abbott#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/09152207\/MedTech-News-for-Artica-Systems-Nevro-Stratus%C2%AE-Medical-Restore-Medical-Respiree-Abbott.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/09152207\/MedTech-News-for-Artica-Systems-Nevro-Stratus%C2%AE-Medical-Restore-Medical-Respiree-Abbott.png","width":772,"height":482,"caption":"MedTech News for Artica Systems, Nevro, Stratus\u00ae Medical, Restore Medical, Respiree, Abbott"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/09152207\/MedTech-News-for-Artica-Systems-Nevro-Stratus%C2%AE-Medical-Restore-Medical-Respiree-Abbott-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Abbott<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ablation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ablation Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Artica Systems<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cryotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cryotherapy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Restore Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Cord Stimulation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Cord Stimulation System<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stratus Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Traumatic Brain Injury<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abbott<\/span>","<span class=\"advgb-post-tax-term\">Ablation Devices<\/span>","<span class=\"advgb-post-tax-term\">Ablation Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Artica Systems<\/span>","<span class=\"advgb-post-tax-term\">cryotherapy<\/span>","<span class=\"advgb-post-tax-term\">Cryotherapy Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Restore Medical<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Stimulation<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Stimulation System<\/span>","<span class=\"advgb-post-tax-term\">Stratus Medical<\/span>","<span class=\"advgb-post-tax-term\">Traumatic Brain Injury<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Mar 9, 2023","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Mar 9, 2023 3:23 pm","modified":"Updated on Sep 18, 2024 3:23 pm"},"featured_img_caption":"MedTech News for Artica Systems, Nevro, Stratus\u00ae Medical, Restore Medical, Respiree, Abbott\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=21623"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21623\/revisions"}],"predecessor-version":[{"id":29637,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21623\/revisions\/29637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/21626"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=21623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=21623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=21623"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=21623"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=21623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}